GGrantIndex
← Leaderboards

Laila Abdullah

James A. Haley Va Medical Center

$2,970,877
Attributed
$3,451,275
Total exposure
10
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $909K · FY201725
$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,451,275 · 6
VA$0 · 4

By mechanism

R21$1,722,251 · 4
R01$1,405,024 · 1
R03$324,000 · 1
I01$0 · 4

Top collaborators

Most similar at James A. Haley Va Medical Center

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Alzheimer&Apos

Research focus

Alzheimer&AposBloodAffectInflammationChronicS DiseaseApolipoprotein ELipidsPre-ClinicalBrainAllelesLifeHigh RiskDiagnosisSymptomsGenotypeImpaired CognitionPlasmaInflammatoryExposure ToAmyloidOmega-3 Fatty AcidsOxidative StressBiological Markers

Grant awards (27)

Neurological effects of aerosolized red tide neurotoxins$700,329
R01 · FY2025 · ES · contact PI
the contribution of APOE4 mediated bioenergetic deficits in the cerebrovascular dysfunction in Alzheimer's disease$0
I01 · FY2025 · VA · contact PI
Neurological effects of aerosolized red tide neurotoxins$704,695
R01 · FY2024 · ES · contact PI
The role of adaptive immunity in organophosphate induced CNS injury$204,300
R21 · FY2024 · NS · contact PI
Influence of APOE genotypes on blood brain barrier transport of DHA by mfsd2a in Alzheimer's Disease$0
I01 · FY2024 · VA · contact PI
Identifying APOE related lipid biomarkers for diagnosing chronic neurocognitive deficits in TBI patients$0
I01 · FY2024 · VA · contact PI
the contribution of APOE4 mediated bioenergetic deficits in the cerebrovascular dysfunction in Alzheimer's disease$0
I01 · FY2024 · VA · contact PI
Cerebrovascular contributions to APOE4-mediated brain bioenergetic deficits in Alzheimer's disease$449,460
R21 · FY2023 · AG · contact PI
The role of adaptive immunity in organophosphate induced CNS injury$244,269
R21 · FY2023 · NS · contact PI
Influence of APOE genotypes on blood brain barrier transport of DHA by mfsd2a in Alzheimer's Disease$0
I01 · FY2023 · VA · contact PI
Identifying APOE related lipid biomarkers for diagnosing chronic neurocognitive deficits in TBI patients$0
I01 · FY2023 · VA · contact PI
The effects of APOE4 on carnitine/acylcarnitine mediated bioenergetic deficits in Alzheimer's disease$162,000
R03 · FY2022 · AG · contact PI
Influence of APOE genotypes on blood brain barrier transport of DHA by mfsd2a in Alzheimer's Disease$0
I01 · FY2022 · VA · contact PI
Identifying APOE related lipid biomarkers for diagnosing chronic neurocognitive deficits in TBI patients$0
I01 · FY2022 · VA · contact PI
Long term assessment of neurological effects after red tide exposure$190,100
R21 · FY2021 · ES · contact PI
The effects of APOE4 on carnitine/acylcarnitine mediated bioenergetic deficits in Alzheimer's disease$162,000
R03 · FY2021 · AG · contact PI
Identifying APOE related lipid biomarkers for diagnosing chronic neurocognitive deficits in TBI patients$0
I01 · FY2021 · VA · contact PI
Influence of APOE genotypes on blood brain barrier transport of DHA by mfsd2a in Alzheimer's Disease$0
I01 · FY2021 · VA · contact PI
Long term assessment of neurological effects after red tide exposure$224,400
R21 · FY2020 · ES · contact PI
Application of lipidomics to identify biomarkers of immune and mitochondrial disturbances in Chronic Fatigue Syndrome.$197,454
R21 · FY2020 · AI · contact PI
Identifying APOE related lipid biomarkers for diagnosing chronic neurocognitive deficits in TBI patients$0
I01 · FY2020 · VA · contact PI
Influence of APOE genotypes on blood brain barrier transport of DHA by mfsd2a in Alzheimer's Disease$0
I01 · FY2020 · VA · contact PI
Application of lipidomics to identify biomarkers of immune and mitochondrial disturbances in Chronic Fatigue Syndrome.$212,268
R21 · FY2019 · AI · contact PI
Identifying APOE related lipid biomarkers for diagnosing chronic neurocognitive deficits in TBI patients$0
I01 · FY2019 · VA · contact PI
Treating GWI immune and metabolic disturbances by targeting lipid metabolism$0
I01 · FY2019 · VA · contact PI
Treating GWI immune and metabolic disturbances by targeting lipid metabolism$0
I01 · FY2018 · VA · contact PI
Treating GWI immune and metabolic disturbances by targeting lipid metabolism$0
I01 · FY2017 · VA · contact PI